JP2005526768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526768A5 JP2005526768A5 JP2003575886A JP2003575886A JP2005526768A5 JP 2005526768 A5 JP2005526768 A5 JP 2005526768A5 JP 2003575886 A JP2003575886 A JP 2003575886A JP 2003575886 A JP2003575886 A JP 2003575886A JP 2005526768 A5 JP2005526768 A5 JP 2005526768A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclic
- saturated
- unsaturated
- branched
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000004122 cyclic group Chemical group 0.000 claims 48
- 229920006395 saturated elastomer Polymers 0.000 claims 39
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 230000002757 inflammatory effect Effects 0.000 claims 10
- -1 1,1-dimethylheptyl Chemical group 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 5
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 5
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 5
- 102000003814 Interleukin-10 Human genes 0.000 claims 5
- 108090000174 Interleukin-10 Proteins 0.000 claims 5
- 102000000588 Interleukin-2 Human genes 0.000 claims 5
- 108010002350 Interleukin-2 Proteins 0.000 claims 5
- 102000004889 Interleukin-6 Human genes 0.000 claims 5
- 108090001005 Interleukin-6 Proteins 0.000 claims 5
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims 5
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims 5
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 5
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 5
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 claims 5
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 claims 5
- 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 claims 5
- 102100024283 Suppressor of cytokine signaling 3 Human genes 0.000 claims 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 5
- 208000027418 Wounds and injury Diseases 0.000 claims 5
- 230000006378 damage Effects 0.000 claims 5
- 208000014674 injury Diseases 0.000 claims 5
- 230000002159 abnormal effect Effects 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 229930194542 Keto Natural products 0.000 claims 3
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical group [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 150000001408 amides Chemical group 0.000 claims 3
- 150000001412 amines Chemical group 0.000 claims 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000006184 cosolvent Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000000839 emulsion Substances 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 125000000468 ketone group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 150000003457 sulfones Chemical group 0.000 claims 3
- 150000003462 sulfoxides Chemical group 0.000 claims 3
- 150000007970 thio esters Chemical group 0.000 claims 3
- 125000001391 thioamide group Chemical group 0.000 claims 3
- 150000003573 thiols Chemical group 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 206010067125 Liver injury Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 206010031149 Osteitis Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000030852 Parasitic disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000035965 Postoperative Complications Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 230000009285 allergic inflammation Effects 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 238000013130 cardiovascular surgery Methods 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 231100000753 hepatic injury Toxicity 0.000 claims 2
- 230000008595 infiltration Effects 0.000 claims 2
- 238000001764 infiltration Methods 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 239000000693 micelle Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000036407 pain Effects 0.000 claims 2
- 244000045947 parasite Species 0.000 claims 2
- 230000036281 parasite infection Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 208000037911 visceral disease Diseases 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- OXFSTTJBVAAALW-UHFFFAOYSA-N 1,3-dihydroimidazole-2-thione Chemical compound SC1=NC=CN1 OXFSTTJBVAAALW-UHFFFAOYSA-N 0.000 claims 1
- QDVBKXJMLILLLB-UHFFFAOYSA-N 1,4'-bipiperidine Chemical compound C1CCCCN1C1CCNCC1 QDVBKXJMLILLLB-UHFFFAOYSA-N 0.000 claims 1
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004856 Lectins Human genes 0.000 claims 1
- 108090001090 Lectins Proteins 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 239000002563 ionic surfactant Substances 0.000 claims 1
- 239000002523 lectin Substances 0.000 claims 1
- 210000002418 meninge Anatomy 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 0 CC1(C)Oc(cc(*)cc2*)c2-c2c1cc1c(C*)c2C1 Chemical compound CC1(C)Oc(cc(*)cc2*)c2-c2c1cc1c(C*)c2C1 0.000 description 5
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL14873602A IL148736A0 (en) | 2002-03-18 | 2002-03-18 | Dexanabinol and dexanabinol analogs which regulate inflammation related genes |
| PCT/IL2003/000223 WO2003077832A2 (en) | 2002-03-18 | 2003-03-16 | Dexanabinol and dexanabinol analogs regulate inflammation related genes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005526768A JP2005526768A (ja) | 2005-09-08 |
| JP2005526768A5 true JP2005526768A5 (enExample) | 2006-01-26 |
Family
ID=27840273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003575886A Abandoned JP2005526768A (ja) | 2002-03-18 | 2003-03-16 | 炎症関連遺伝子を調節するデキサナビノール及びデキサナビノール類似体 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1485083A4 (enExample) |
| JP (1) | JP2005526768A (enExample) |
| AU (1) | AU2003214608A1 (enExample) |
| CA (1) | CA2479676A1 (enExample) |
| IL (1) | IL148736A0 (enExample) |
| WO (1) | WO2003077832A2 (enExample) |
| ZA (1) | ZA200407182B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0326393D0 (en) * | 2003-11-12 | 2003-12-17 | Ares Trading Sa | Cytokine antagonist molecules |
| EP1774328A1 (en) * | 2004-07-23 | 2007-04-18 | Novartis AG | Biomarkers for rheumatoid arthritis (ra) |
| US20080262079A1 (en) * | 2004-08-09 | 2008-10-23 | Bernard Mach | Cannabinoid Compositions and Methods of Use Thereof |
| HRP20090646T1 (hr) * | 2005-03-17 | 2010-01-31 | Proyecto De Biomedicina Cima | Uporaba 5'-metiltioadenozina (mta) kod prevencije i/ili liječenja autoimunih bolesti i/ili odbacivanje transplantata |
| EP1752149A1 (en) * | 2005-07-29 | 2007-02-14 | Laboratorios Del Dr. Esteve, S.A. | CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression |
| PT1903866E (pt) * | 2005-11-07 | 2016-06-09 | Murty Pharmaceuticals Inc | Distribuição melhorada de tetra-hidrocanabinol |
| CN102851295B (zh) * | 2006-08-28 | 2015-01-07 | 长春华普生物技术有限公司 | Toll 样受体调节性寡核苷酸及其用途 |
| GB0713116D0 (en) * | 2007-07-06 | 2007-08-15 | Therapeutics Ltd E | Treatment of melanoma |
| GB0719771D0 (en) * | 2007-10-10 | 2007-11-21 | Therapeutics Ltd E | Dexanabinol in combination with inhibitors of BRAF or MEK for the treatment of melanoma |
| GB0915877D0 (en) * | 2009-09-10 | 2009-10-14 | E Therapeutics Plc | Cancer cell apoptosis |
| GB201207305D0 (en) | 2012-04-26 | 2012-06-13 | E Therapeutics Plc | Therapy |
| WO2014021455A1 (ja) * | 2012-08-03 | 2014-02-06 | 国立大学法人愛媛大学 | 免疫細胞の活性化抑制剤およびその用途 |
| JP2017031120A (ja) * | 2015-08-05 | 2017-02-09 | オリザ油化株式会社 | ＴＮＦ−α及びＩＬ−６産生抑制剤及びそれを用いた筋肉炎症抑制剤 |
| WO2017068349A1 (en) | 2015-10-23 | 2017-04-27 | E-Therapeutics Plc | Cannabinoid for use in immunotherapy |
| WO2018163716A1 (ja) * | 2017-03-08 | 2018-09-13 | 日清オイリオグループ株式会社 | 抗炎症剤、抗炎症用医薬組成物、抗炎症用食品組成物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL115245A (en) * | 1995-09-11 | 2002-12-01 | Yissum Res Dev Co | Tumor necrosis factor inhibiting pharmaceuticals |
| CA2411585A1 (en) * | 2000-06-22 | 2001-12-27 | Pharmos Corporation | Novel non-psychotropic cannabinoids |
-
2002
- 2002-03-18 IL IL14873602A patent/IL148736A0/xx unknown
-
2003
- 2003-03-16 CA CA002479676A patent/CA2479676A1/en not_active Abandoned
- 2003-03-16 JP JP2003575886A patent/JP2005526768A/ja not_active Abandoned
- 2003-03-16 AU AU2003214608A patent/AU2003214608A1/en not_active Abandoned
- 2003-03-16 WO PCT/IL2003/000223 patent/WO2003077832A2/en not_active Ceased
- 2003-03-16 EP EP03710188A patent/EP1485083A4/en not_active Withdrawn
-
2004
- 2004-09-08 ZA ZA200407182A patent/ZA200407182B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2330858C2 (ru) | Новые соединения, составы и способы лечения воспалительных заболеваний и состояний | |
| US20220062222A1 (en) | Cromolyn esters and uses thereof | |
| US12612391B2 (en) | Cromolyn derivatives and uses thereof | |
| JP2022529315A5 (enExample) | ||
| US20080161275A1 (en) | Compositions and methods for the treatment of inflammatory disease | |
| US8716238B2 (en) | Cyclosporin derivatives for treating ocular and dermal diseases and conditions | |
| JP2009545527A (ja) | 粘膜炎の治療用の組成物及び方法 | |
| HUT53286A (en) | Process for production of medical compositions containing as active substance dihydrolipone acid | |
| EP2207543A2 (en) | Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for treating autoimmune diseases or inhibiting immune function | |
| JP2006501298A5 (enExample) | ||
| RU2468793C2 (ru) | Композиции на основе соединений 2-амино-1,3-пропандиола | |
| WO2004031160A2 (fr) | Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete | |
| EP4574822A3 (en) | Compounds and compositions for use in treating skin disorders | |
| JP2025508359A5 (enExample) | ||
| CN1111128A (zh) | 含吡氧噻嗪的皮肤表面抗炎组合物 | |
| RU2008139988A (ru) | Применение производных 3,5-втор-4-норхолестана для получения лекарственного средства-цитопротектора | |
| CN1638756A (zh) | 左旋(r)班布特罗及其药物用途 | |
| JP2006509038A5 (enExample) | ||
| RU2013113301A (ru) | Замещенные 2-оксо- и 2-тиоксо-дигидрохинолин-3-карбоксамиды в качестве модуляторов kcnq2/3 | |
| JP2008543821A5 (enExample) | ||
| FR2577552A1 (fr) | Esters heterocycliques dissymetriques d'acides 1,4-dihydropyridine-3,5-dicarboxyliques, procede de preparation et utilisation en therapeutique | |
| JP2004506010A5 (enExample) | ||
| US20060177517A1 (en) | Antiinflammtory agent and antiinflammatory medical material | |
| US20100137429A1 (en) | Composition for transdermal or transmucosal administration | |
| EP4635492A3 (en) | Tryptamines and methods of treating mood disorders |